Precision medicine company CareDx and 10x Genomics have partnered to launch ImmuneScape, a multiomics program to improve the understanding of transplant organ rejection and variability in patient ...
8 analysts have shared their evaluations of 10x Genomics (NASDAQ:TXG) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ...
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale. Debuts at AACR Annual Meeting 2026 ...
Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and ...
PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to ...
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc.
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...
Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results